2012 T. T. Chao Symposium on Innovation: “From Base Pairs to Bedside: What Happens When Genomics-Based Therapies Enter Our Clinics”
James D. Watson delivers opening remarks at CHF's 2012 T. T. Chao Symposium.
CHF’s annual T. T. Chao Symposium celebrates and encourages innovation in the Houston region. The 2012 symposium, “From Base Pairs to Bedside: What Happens When Genomics-Based Therapies Enter Our Clinics,” examined personalized medicine, from its promise for future health care to its social ramifications and the ethical questions it raises.
Opening remarks were delivered by James D. Watson, Chancellor Emeritus, Cold Spring Harbor Laboratories, Watson School of Biological Sciences.
Challenges and Opportunities for the Private and Public Sectors: A conversation about genomics-based therapies.
- John Mendelsohn, former President, University of Texas M. D. Anderson Cancer Center, and current Director, M. D. Anderson’s Khalifa Institute for Personalized Cancer Therapy
- Leroy Hood, President and Cofounder, Institute for Systems Biology
- Nancy Chang, Cofounder, Tanox, Inc.
- Bradley Ozenberger, Program Director, Technology Development for the National Human Genome Research Institute, and Program Director, The Cancer Genome Atlas, National Institutes of Health
Patient Tissue and Medical Information: Issues of Ownership, Access, and Privacy: A conversation on ownership rights, patient privacy, and biomedical research as viewed by the laws governing access to tissues, medical information, intellectual property, and protection of privacy.
- Hans Sauer, Deputy General Counsel for Intellectual Property, Biotechnology Industry Organization
- Barbara Evans, Professor of Law and Codirector, Health Law and Policy Institute, University of Houston Law Center